# Foghorn Therapeutics

Source: https://onco.cc/companies/foghorn-therapeutics/  
OnCo record `foghorn-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Foghorn Therapeutics makes drugs that act on the machinery that packages DNA and controls which genes are switched on. Its lead drug, partnered with Lilly, targets lung cancers that have lost a gene called SMARCA4.

## Summary

Foghorn Therapeutics is a Cambridge, Massachusetts company targeting the chromatin regulatory system through its Gene Traffic Control platform. Its most advanced programme, FHD-909 (LY4050784), is a selective SMARCA2 ATPase inhibitor in phase 1 for SMARCA4-mutant non-small cell lung cancer, partnered with Lilly under a 50/50 US economic split with ex-US royalties; the Lilly collaboration also covers a selective SMARCA2 degrader and other programmes. Wholly owned preclinical programmes include a selective EP300 degrader for multiple myeloma, DLBCL and prostate cancer (IND targeted in 2027), a selective CBP degrader for ER-positive breast cancer, and a selective ARID1B degrader for ARID1A-mutant cancers. Foghorn also signed a collaboration with Merck in July 2020 (15 million US dollars upfront). Foghorn raised 135.2 million US dollars gross in its October 2020 Nasdaq IPO.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Cambridge, MA
- Type: biotech
- Website: https://www.foghorntx.com/
- Ticker: FHTX

## Notes

- The website blocks curl (HTTP 403) but was fetched successfully with WebFetch. Founding year and the Lilly deal terms (2021) not sourced beyond the pipeline page.

## Sources

- Official website: https://www.foghorntx.com/
- Pipeline: https://www.foghorntx.com/pipeline/
- Q3 2020 results noting IPO (SEC exhibit): https://www.sec.gov/Archives/edgar/data/1822462/000119312520310711/d98800dex991.htm

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Epigenetic & Transcriptional Therapy](https://onco.cc/fronts/epigenetics/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)](https://onco.cc/technologies/epigenetic-drugs/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/), [Synthetic lethality approaches](https://onco.cc/technologies/synthetic-lethality-approaches/)
- companies: [Flagship Pioneering](https://onco.cc/companies/flagship-pioneering/)
- trials: [SMARCA4/2 Inhibitor for POU2F3-Positive SCLC](https://onco.cc/trials/nct07551635/)

---
JSON: https://onco.cc/api/v1/entities/foghorn-therapeutics.json